Clinical Trial

Induction Chemotherapy for Locally Recurrent Rectal Cancer

Study acronym: PelvEx II
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 6, 2022 (before its estimated March 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a multicentre, open-label, parallel arms, phase IIII study that randomises patients with locally recurrent rectal cancer in a 1:1 ratio to receive either induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery (experimental arm) or neoadjuvant chemoradiotherapy and surgery alone (control arm)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-05-11; most recent amendment 2022-09-01.
Status change: Not Yet Recruiting → Recruiting 2020-12-10
Trial Details
NCT Number NCT04389086
Lead Sponsor Catharina Ziekenhuis Eindhoven
Conditions Recurrent Rectal Cancer
Enrollment 364 participants
Start Date 2020-11-13
Primary Completion 2024-03-01 (estimated)
Study Completion 2030-03-01 (estimated)
Updated on ClinicalTrials.gov 2022-09-06